Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (January 2018)

18 slides from Titan Pharmaceuticals's investor presentation, Jan 8, 2018

  1. Slide 1: Corporate Presentation | January 2018

    TITAN PHARMACEUTICALS © 2018 TITAN PHARMACEUTICALS INC. | NASDAQ:TTNP CORPORATE PRESENTATION | JANUARY 2018

  2. Slide 2: Forward-Looking Statements

    The presentation may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Reference is made in particular to the description of our plans and objectives for future operations, assumptions und

  3. Slide 3: Company Snapshot

    3 ProNeura TM drug delivery platform provides long - term, continuous, non - fluctuating medication levels FDA approved Probuphine ® (buprenorphine) implant: six - month maintenance treatment of opioid use disorder (OUD) • US and Canada: Braeburn Pharmaceuticals (U.S. launch start - Q1 2017) • Europ

  4. Slide 4: ProNeura Long-Term Drug Delivery Platform

    4 • Active pharmaceutical ingredient (API) uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Controlled rate of drug delivery and essentially 100 % bioavailability • Intellectual Property • Issued method of use p

  5. Slide 5: ProNeura Mechanism of Action

    5 • Inserted subdermally • Drug is released continuously into patient's body through the process of dissolution • Results in a stable level of medication in the blood, avoiding peaks and troughs of oral dosing • Round - the - clock long - term treatment (3 - 12 months) in outpatient setting PRONEURA

  6. Slide 6: ProNeura Product Pipeline

    6 CANDIDATE INDICATION DEVELOPMENT STAGE Probuphine (United States) OUD Probuphine (European Union) OUD Ropinirole Implant Parkinson’s Disease T3 Implant Hypothyroidism PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET PR

  7. Slide 7: Probuphine Implant FDA Approved for Maintenance Treatment of OUD

    7 PATIENTS Major epidemic: ~ 2.5 million people in U.S. affected TREATMENT Buprenorphine treatment is the gold standard ADVANTAGES Controls withdrawal symptoms and cravings without opioid euphoria; convenient outpatient treatment CHALLENGES Daily dosed formulations present various challenges: compli

  8. Slide 8: Probuphine U.S. Commercial Launch Initiated Q1 2017

    8 Partnership with Braeburn Pharmaceuticals for U.S. and Canada* • Tiered royalties on net sales of m id - teens to low 20s (%) - U.S. Patent term to April 2024 • Sales Milestones of up to $165 million • Braeburn launched with 60+ field sales force and medical support staff focusing on 80+ key U.S.

  9. Slide 9: Probuphine European Commercialization Plans

    9 Advancing European opportunity for regulatory approval and commercial licensing: • March/April 2017: EMA confirmed eligibility for review and approval under centralized procedure and granted pediatric indication waiver • July 2017: received positive input at pre - MAA meetings from rapporteur (Ire

  10. Slide 10: Parkinson's Disease (PD) Overview

    Characterized by the loss of dopamine, which alters activity in the brain region impacting movement and motor function • Treated with drugs designed to replace or mimic dopamine in the brain • After several years of daily dosed pulsatile treatment, these drugs can lose benefit and trigger serious si

  11. Slide 11: Parkinson's Disease Market and Cost Data

    11 * GlobalData; **Parkinson’s Action Network, National Center for Health Statistics; “The Current and Projected Economic Burden of Parkinson’s Disease in the United States” Movement Disorders, March 2013 Based on information from Titan and other sources believed to be reliable and prepared exclusiv

  12. Slide 12: ProNeura Parkinson's Disease Program

    12 • Ropinirole (Requip ® ), a dopamine agonist marketed by GSK for PD • Evaluated in a Parkinsonian animal model using ProNeura drug delivery platform • Results presented in June 2015 - 19th International Congress of Parkinson's Disease and Movement Disorders • Sustained plasma ropinirole levels fo

  13. Slide 13: Ropinirole Implant Program

    2018 2017 13 Investigational New Drug Application cleared by FDA in late August 2017 Study completion is expected by the end of 2018 Data from the first patient cohort should be available in first half of 2018 following completion of the three - month treatment STUDY GOALS • Characterize pharmacokin

  14. Slide 14: ProNeura Other Opportunities

    14 Malaria Prophylaxis: • Collaboration with Walter Reed Army Institute of Research (WRAIR) and Southwest Research Institute (SWRI) • Anti - malarial drug implant to provide prophylactic treatment for personnel in malaria endemic regions • Initial non - clinical studies show positive results and for

  15. Slide 15: Titan Pharmaceuticals Executive Management

    15 Marc Rubin, M.D. Executive Chairman & Director • 11 years with Titan • Former Head of Global R&D and member of the Board of Management at Bayer Pharma • Executive R&D and commercial responsibilities at GSK for 13 years • 28 years in the pharmaceutical industry following 7 years at NIH Sunil Bhons

  16. Slide 16: Thank You. Questions?

    THANK YOU. QUESTIONS? © 2018 TITAN PHARMACEUTICALS INC. | NASDAQ:TTNP CORPORATE PRESENTATION | JANUARY 2018

  17. Slide 17: Appendix: Probuphine Risk Evaluation & Mitigation Strategy

    Appendix PROBUPHINE RISK EVALUATION & MITIGATION STRATEGY

  18. Slide 18: Probuphine REMS: Training, Counseling and Closed Distribution

    Training and Certification Providers who prescribe and implant Probuphine are required to: • Attend Live Training: Lecture and Practicum • Complete the Probuphine REMS Program Knowledge Assessment • E nrolled in the Probuphine REMS program • Providers who perform Probuphine surgical procedures must

Titan Pharmaceuticals — Investor Presentation (January 2018) on 6ix